Please login to the form below

Not currently logged in
Email:
Password:

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... During 2016 Eloctate and Alprolix generated

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics